ISRCTN70607799 https://doi.org/10.1186/ISRCTN70607799

A study in healthy volunteers to look at safety and tolerability of ALKS 4510

Submission date 06/05/2025	**Recruitment status** Recruiting	[ ] Prospectively registered [ ] Protocol [ ] Statistical analysis plan [ ] Results [ ] Individual participant data [X] Record updated in last year
Registration date 20/05/2025	**Overall study status** Ongoing	
Last Edited 19/05/2025	**Condition category** Other	

Plain English summary of protocol

Background and study aims
This clinical study assesses how safe and well-tolerated an investigational drug is in a healthy adult population.

Who can participate?
Healthy adults aged 18-55 years

What does the study involve?
Part 1 is designed to assess the effect of a single dose of ALKS 4510 in healthy participants. Participants will have three study visits, which include a screening, a treatment period with four consecutive overnight stays, and a safety follow-up.

Part 2 is designed to assess the effect of multiple daily doses of ALKS 4510 in healthy participants. Participants will have 3 study visits, which include a screening, a treatment period with 12 consecutive overnight stays and a safety follow-up.

What are the possible benefits and risks of participating?
This is a phase 1 healthy volunteer study, and participants will be administered the study drug for research purposes only. This trial may help reveal important scientific knowledge that could contribute to the development of a drug.

As with all interventional studies, the drug treatment may involve side effects. Participants will be carefully monitored for any side effects; however, not all of the side effects that the study drug may have are known.

Where is the study run from?
Alkermes, Inc. (USA). The study is conducted at a phase 1 clinical trial site in Australia

When is the study starting and how long is it expected to run for?
May 2025 to November 2025

Who is funding the study?
Alkermes, Inc. (USA)

Who is the main contact?
Clinicaltrials@alkermes.com

Contact information

Type(s)
Public, Scientific

Contact name
Ms Clinical Operations

Contact details
Alkermes
900 Winter Street
Waltham
United States of America
02451
+1 571-599-2702
clinicaltrials@alkermes.com

Type(s)
Principal Investigator

Contact name
Ms Clinical Operations

Contact details
Bright Building, Level 5
Corner High and Avoca Street
Randwick
Australia
NSW 2031
+1 571-599-2702
clinicaltrials@alkermes.com

Additional identifiers

EudraCT/CTIS number
Nil known

IRAS number

ClinicalTrials.gov number
Nil known

Secondary identifying numbers
ALKS 4510-101

Study information

Scientific Title
A randomized, double-blind, placebo-controlled, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALKS 4510 in healthy subjects

Study objectives
Study to assess the safety, tolerability and pharmacokinetics of single-ascending and multiple-ascending doses of ALKS 4510

Ethics approval required
Ethics approval required

Ethics approval(s)
Submitted 19/03/2025, Bellberry Human Research Ethics Committee (HREC) (123 Glen Osmond Road, Eastwood, 5063, Australia; +61 9 8361 3222; bbl@bellberry.com.au), ref: 2025-02-229

Study design
Single-centre randomized double-blind placebo-controlled study

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Other

Study type(s)
Safety

Participant information sheet
No participant information sheet available

Health condition(s) or problem(s) studied
Phase 1 study drug

Interventions
Part 1 SAD: Healthy volunteers will be randomized by using a randomization code to receive a single dose of oral ALKS 4510 or placebo for 1 day in each of five cohorts
Part 2 MAD: Healthy volunteers will be randomized by using a randomization code to receive one dose of oral ALKS 4510 or placebo every day for 10 consecutive days in each of four cohorts

Intervention Type
Drug

Pharmaceutical study type(s)
Pharmacokinetic, Dose response

Phase
Phase I

Drug/device/biological/vaccine name(s)
ALKS 4510

Primary outcome measure
Incidence of Treatment-Emergent Adverse Events by monitoring case report forms through dosing and safety follow up to 17 days

Secondary outcome measures
Levels of ALKS 4510 in blood measured as Cmax , Tmax (Day 1), AUC (over 12 hours), T-half, CL /F, and Vz/F using pharmacokinetic non-compartmental methods at 3 study visits with duration of participation of about 17 days

Overall study start date
31/05/2024

Completion date
30/11/2025

Eligibility

Key inclusion criteria
1. Participants must be 18 to 55 years of age, inclusive, at the time of informed consent
2. Willing and able to provide informed consent before study participation
3. Has a BMI ≥18 and ≤30 kg/m2
4. Is overtly healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, vital signs, and safety ECGs
5. Must adhere to contraceptive use

Participant type(s)
Healthy volunteer

Age group
Adult

Lower age limit
18 Years

Upper age limit
55 Years

Sex
Both

Target number of participants
72

Key exclusion criteria

1. Subjects who have demonstrated allergic reactions (eg, food, drug, atopic reactions, or asthmatic episodes) which, in the opinion of the Investigator, interfere with their ability to participate in the study
2. The subject has poor peripheral venous access
3. Clinically significant illness or disease (eg, psychiatric disorders, disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system (including any sleep disorder such as sleep apnea or narcolepsy), or cardiovascular system, infection, visual conditions, or subjects who have a congenital abnormality in metabolism)
4. Any history at Screening of gastrointestinal or renal surgery that may affect PK profiles of ALKS 4510 (eg, hepatectomy, nephrectomy, digestive organ resection, or surgery that alters the gastrointestinal tract without resection), or other conditions that may impact absorption (malabsorption syndrome, inflammatory bowel disease, etc). Uncomplicated appendectomy and /or hernia repair are allowed
5. Is currently pregnant or breastfeeding, or is planning to become pregnant during the study

Date of first enrolment
12/05/2025

Date of final enrolment
30/11/2025

Locations

Countries of recruitment
Australia

Study participating centre
Scientia Clinical Research Limited
Bright Building, Level 5
Corner High and Avoca Street
Randwick
Australia
2031

Sponsor information

Organisation
Alkermes (United States)

Sponsor details
900 Winter Street
Waltham
United States of America

02451
+1 571-599-2702
clinicaltrials@alkermes.com

Sponsor type
Industry

Website
https://www.alkermes.com/

ROR
https://ror.org/038hqfn26

Funder(s)

Funder type
Industry

Funder Name
Alkermes

Alternative Name(s)
Alkermes plc

Funding Body Type
Government organisation

Funding Body Subtype
For-profit companies (industry)

Location
Ireland

Results and Publications

Publication and dissemination plan
Planned publication in a peer-reviewed journal

Intention to publish date
01/11/2026

Individual participant data (IPD) sharing plan
The datasets generated during and/or analysed during the current study are not expected to be made available as they are intellectual property

IPD sharing plan summary

Not expected to be made available